Lack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats.
Here we show that Doxil has minimal antitumour activity in the isolated limb perfusion (ILP) setting and its activity was not enhanced by the addition of tumour necrosis factor (TNF). Doxil accumulation in tumour tissue was low and also not augmented by TNF. In contrast, activity of free conventional doxorubicin was enhanced by TNF. We conclude that application of Doxil in a TNF-based ILP is not a useful alternative to free conventional doxorubicin or melphalan.
ten Hagen
T L M
TL
Laboratory of Experimental Surgical Oncology, Department of Surgical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands. t.l.m.tenhagen@erasmusmc.nl
Hoving
S
S
Ambagtsheer
G
G
van Tiel
S T
ST
Eggermont
A M M
AM
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D010478:Chemotherapy, Cancer, Regional Perfusion; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000494:pharmacology*; D006614:Hindlimb / Q000187:drug effects / Q000473:pathology; D006801:Humans; D008297:Male; D009924:Organ Culture Techniques; D051381:Rats; D012509:Sarcoma / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D000903:Antibiotics, Antineoplastic; D014409:Tumor Necrosis Factor-alpha; D004317:Doxorubicin